Industry
Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
Total Companies
1 301
1 248 stocks
| Company | Last Price | Price Change | Market Cap | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$1 004.92 |
0%
|
$949.5B |
|
|
|
Johnson & Johnson
JNJ
|
$226.71 |
-1.8%
|
$546.1B |
|
|
|
Roche Holding AG
ROG
|
CHf324.9 |
+4.1%
|
$335.7B |
|
|
|
Novartis AG
NOVN
|
CHf117.26 |
+0.4%
|
$287.3B |
|
|
|
AstraZeneca PLC
AZN
|
GBX13 632 |
-0.8%
|
$283.5B |
|
|
|
Merck & Co Inc
MRK
|
$111.38 |
-1.8%
|
$275.1B |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr299.2 |
+0.9%
|
$207.3B |
|
|
|
Pfizer Inc
PFE
|
$25.33 |
-1.6%
|
$144.1B |
|
|
|
Bristol-Myers Squibb Co
BMY
|
$57 |
+0.4%
|
$116.4B |
1 243 results hidden
Create a free account to unlock additional access and upgrade to see all results
Create Free Account
